ライフサイエンスコーパス: CARM1

1 CARM1 and p300 cooperate with BRCA1 and p53 to induce ex

2 CARM1 and PRMT1 are transcriptional coactivators that de

3 CARM1 contains a conserved protein arginine methyltransf

4 CARM1 facilitated Tax transactivation of the CREB-depend

5 CARM1 is a protein arginine methyltransferase (PRMT) tha

6 CARM1 is an arginine methyltransferase with diverse hist

7 CARM1 is one of nine protein arginine methyltransferases

8 CARM1 is recruited by many different transcription facto

9 CARM1 is specifically required for the estrogen-induced

10 CARM1 methylates histone H3 and other factors including

11 CARM1 methyltransferase activity was required for induct

12 CARM1 orchestrates this coactivator activity in part by

13 CARM1 overexpression has been reported in multiple cance

14 CARM1 promotes MAD2L2 silencing by driving the switch fr

15 CARM1 recruitment lags behind the binding of SRC-3 and p

16 CARM1 regulates this nuclear retention pathway at two le

17 CARM1 requires its enzymatic activity for all of its kno

18 CARM1 selective hits were further validated by orthogona

19 CARM1 synergizes with CIITA in activating MHC-II transcr

20 CARM1 was evidenced as an ERalpha coactivator in cell-ba

21 CARM1 was localized in hippocampal post-synapses, with i

22 CARM1, which is necessary for MCP-1 expression, was not

23 tor-associated arginine methyltransferase 1 (CARM1) action are critical to E2-stimulated gene express

24 tor-associated arginine methyltransferase 1 (CARM1) activity.

25 tor-associated arginine methyltransferase 1 (CARM1) and prevents its correct cellular localization du

26 es coactivator arginine methyltransferase 1 (CARM1) and protein arginine methyltransferase 6 (PRMT6)

27 tor-associated arginine methyltransferase 1 (CARM1) as a crucial component of autophagy in mammals.

28 tor-associated arginine methyltransferase 1 (CARM1) is a coactivator for a number of transcription fa

29 tor-associated arginine methyltransferase 1 (CARM1) is a dual functional coregulator that facilitates

30 tor associated arginine methyltransferase 1 (CARM1) is a member of the protein arginine methyltransfe

31 tor-associated arginine methyltransferase 1 (CARM1) is a propitious target for cancer therapy; howeve

32 tor-associated arginine methyltransferase 1 (CARM1) is a protein arginine methyltransferase that meth

33 tor-associated arginine methyltransferase 1 (CARM1) is a protein methyltransferase that negatively re

34 tor-associated arginine methyltransferase 1 (CARM1) is subjected to multiple post-translational modif

35 tor-associated arginine methyltransferase 1 (CARM1) methylates Arg 754 in the KIX region of coactivat

36 tor-associated arginine methyltransferase 1 (CARM1) methylates Pontin chromatin-remodeling factor und

37 tor-associated arginine methyltransferase 1 (CARM1), a coactivator for various cancer-relevant transc

38 tor-associated arginine methyltransferase 1 (CARM1), a unique coactivator of ERalpha that can simulta

39 tor-associated arginine methyltransferase 1 (CARM1), both in in vitro and cellular settings.

40 tor-associated arginine methyltransferase 1 (CARM1), providing insight into the unrecognized function

41 tor-associated arginine methyltransferase 1 (CARM1), the histone arginine methyltransferase and coact

42 tor-associated arginine methyltransferase 1 (CARM1), which methylates histone H3 and other proteins s

43 tor-associated arginine methyltransferase 1 (CARM1)-mediated histone methylation has been shown to ac

44 tor-associated arginine methyltransferase 1 (CARM1).

45 tor-associated arginine methyltransferase 1 (CARM1).

46 tor-associated arginine methyltransferase 1 (CARM1/PRMT4) binds the p160 family of steroid receptor c

47 tor-associated arginine methyltransferase 1, CARM1.

48 virtual screening approaches, we identify 11 CARM1 (PRMT4) inhibitors with ligand efficiencies rangin

49 We identified >130 CARM1 protein substrates and validated in vitro >90% of

50 thylation promotes dissociation of the SRC-3/CARM1 coactivator complex.

51 the spinal muscular atrophy protein SMN in a CARM1-dependent fashion.

52 ate-ribose) polymerase (PARP) inhibitor in a CARM1-dependent manner.

53 uited to an estrogen-responsive element in a CARM1-dependent manner.

54 differentiation of Carm1(-/-) FL cells in a CARM1-sufficient host showed that CARM1 is required cell

55 oorly to and did not cooperate with PRMT1, a CARM1-related protein arginine methyltransferase that al

56 nds of optimization produced 27 (SGC2085), a CARM1 inhibitor with an IC50 of 50 nM and more than hund

57 In adults, CARM1 is overexpressed in human grade-III breast tumors

58 Although CARM1 and its asymmetrically deposited dimethylation at

59 Although CARM1 is expressed in the neural crest region in early d

60 Significant synergy was observed among CARM1, p300 and GRIP1, which is dependent on the interac

61 ear factor (NF)-kappaB signaling (CARD14 and CARM1).

62 pts encoding full-length CARM1 (CARM1FL) and CARM1 with exon 15 deleted (CARM1DeltaE15) exist in cell

63 tor and secondary coactivators, p300/CBP and CARM1.

64 ated with a simultaneous increase of FXR and CARM1 occupation.

65 h other NR coactivators, including GRIP1 and CARM1, to enhance estrogen receptor function.

66 which, with the help of CARM1 inhibitor and CARM1 morpholinos, we show that inhibition of H3R17 meth

67 MYPT1 and CARM1 also function to alter OGT substrate specificity i

68 We demonstrate here that MYPT1 and CARM1 also interact with and target OGT.

69 MYPT1 and CARM1 are substrates of OGT in vitro and in vivo.

70 is dependent on the interaction of p300 and CARM1 with the AD1 and AD2 domains of GRIP1, respectivel

71 or coactivator synergy among p160, p300, and CARM1 coactivators.

72 erophospholipid metablism, h-Efp pathway and CARM1 and Regulation of Estrogen Receptor, which can be

73 rotein arginine methyltransferases PRMT1 and CARM1 in p53 function; (2) both independent and ordered

74 methyltransferases, G9a, SUV39H1, PRMT1 and CARM1.

75 ed cooperative functions of p300, PRMT1, and CARM1; and (3) mechanisms that involve direct interactio

76 physical interaction between HTLV-1 Tax and CARM1 was demonstrated using in vitro glutathione S-tran

77 As CARM1 is a potent transcriptional coactivator of estroge

78 s is the first report of compounds acting as CARM1 activators.

79 EFs, suggesting a synergistic effect between CARM1 and PRMT6 inhibitions.

80 V-1 LTR through a direct interaction between CARM1 and Tax and this binding promotes methylation of h

81 ast two-hybrid screen for proteins that bind CARM1 identified the protein Flightless I (Fli-I), which

82 Embryos that are null for both CARM1 and PRMT6 are noticeably smaller than CARM1 null e

83 t its enzymatic activity, it did impair both CARM1-activated transcription and pre-mRNA splicing.

84 Therefore, histone methylation at Arg-17 by CARM1 is a downstream target of signaling through ligand

85 he increased occupation of the BSEP locus by CARM1 also corresponds with the increased deposition of

86 n of splicing factors that are methylated by CARM1, and protein-protein interactions that are regulat

87 factors that are specifically methylated by CARM1.

88 600 is a site for regulatory methylation by CARM1/PRMT4, which negates the CREB-binding function of

89 e required methylation of Arg 754 of p300 by CARM1.

90 n-protein interactions that are regulated by CARM1, strongly implicates this enzyme in the regulation

91 onal and temporal relationships among CIITA, CARM1, and CBP for IFN-gamma induction of MHC-II.

92 strates the coordinated regulation of CIITA, CARM1, and the acetyltransferase cyclic-AMP response ele

93 A kinetic analysis shows that CIITA, CARM1, and H3-R17 methylation all precede CBP loading on

94 ions enhanced the binding of the coactivator CARM1 to the distal regulatory region.

95 uding those sites methylated by coactivators CARM1 (H3 Arg17) and PRMT1 (H4 Arg3).

96 ediated enhanced recruitment of coactivators CARM1 and p300 to GR target genes.

97 dependent activation of the ERalpha-cofactor CARM1.

98 serves as a molecular switch for controlling CARM1 enzymatic activity during the cell cycle.

99 when an arginine methyltransferase-defective CARM1 mutant is used.

100 ysine to create an automethylation-deficient CARM1.

101 tide sequences derived from the well-defined CARM1 substrate poly(A)-binding protein 1 (PABP1) were c

102 Furthermore, either CARM1 knockdown or CARM1 enzyme-deficient mutant knockin

103 In the process of purifying endogenous CARM1-interacting proteins, we identified an associated

104 Although the histone methylation enzyme CARM1 and an ATP-remodeling complex have been individual

105 ious target for cancer therapy; however, few CARM1 substrates are known, and its mechanism of substra

106 Consistent with these findings, CARM1 led to increased BSEP promoter activity with an in

107 R26-methylase CARM1 and is lowered following CARM1 inhibition, indicating the importance of epigeneti

108 icing not only serves as the determinant for CARM1 automethylation but also generates cell type-speci

109 ledge, the first demonstration of a role for CARM1 in multiple myeloma (MM).

110 site for p300/CBP) and AD2 (binding site for CARM1) activation domains of GRIP1 contributed to the sy

111 strates than CARM1, could not substitute for CARM1 to act synergistically with p300 or p/CAF.

112 reviously identified in vitro substrates for CARM1.

113 s a self-regulatory signaling mechanism from CARM1's catalytic domain to its CTD.

114 Furthermore, CARM1-mediated BAF155 methylation affects gene expressio

115 The synergy between GRIP1, CARM1, and Fli-I required the methyltransferase activity

116 criptional synergy among coactivators GRIP1, CARM1, p300 and CoCoA.

117 CoCoA cooperated synergistically with GRIP1, CARM1, and p300 to enhance ER-mediated transcription.

118 sociation of ATP-remodeling factors with HMT CARM1 defines a new component of regulation in the nucle

119 However, CARM1 methylates histone H3, PABP1, AIB1, and a number o

120 However, CARM1-dependent methylation of histone H3 was not observ

121 at, when EZH2 is functionally silenced, HR+, CARM1-high, high-grade serous ovarian cancer cells becom

122 tor-associated arginine methyltransferase I (CARM1; PRMT4) regulates gene expression by multiple mech

123 These studies identify CARM1 as a potential new target in the treatment of estr

124 ha-regulated cellular processes, implicating CARM1 as a putative epigenetic target in ER-positive bre

125 However, the gross levels of H3R17me2a in CARM1 KO mice did not significantly decrease, indicating

126 e H3 tails harboring dimethylation at R17 in CARM1-methylated histone octamers.

127 erves as a unique mechanism for inactivating CARM1-regulated estrogen-dependent gene expression.

128 st, transfection of a catalytically inactive CARM1 methyltransferase mutant did not enhance Tax trans

129 portance of multiple coactivators, including CARM1 and its specific protein methyltransferase activit

130 lear receptor coactivator complex, including CARM1, p300/CBP, and GRIP1 (one of the p160 coactivators

131 Indeed, CARM1 is found to interact with a number of proteins and

132 Nonetheless, these are sites of E2-induced CARM1 activity.

133 vivo, Ser2 or Ser5 phosphorylation inhibits CARM1 activity toward this site in vitro, suggesting tha

134 whereas estrogen stimulation of cyclin D1 is CARM1 independent.

135 of SRC-3 was localized to an arginine in its CARM1 binding region and correlated with decreased estro

136 The methylation of two known CARM1 substrates, poly(A)-binding protein (PABP1) and th

137 Mice lacking CARM1 are small, fail to breathe and die shortly after b

138 ses demonstrate that lungs from mice lacking CARM1 have immature alveolar type II cells and an absenc

139 The lungs of newborn mice lacking CARM1 have substantially reduced airspace compared with

140 alternative transcripts encoding full-length CARM1 (CARM1FL) and CARM1 with exon 15 deleted (CARM1Del

141 his nuclear retention pathway at two levels: CARM1 methylates the coiled-coil domain of p54(nrb), res

142 cts with other proteins that help to mediate CARM1 coactivator function.

143 ed expression of the histone H3R26-methylase CARM1 and is lowered following CARM1 inhibition, indicat

144 In the NUMAC complex, the methylase, CARM1, acquires the ability to covalently modify nucleos

145 egulation via the arginine methyltransferase CARM1 (coactivator-associated arginine methyltransferase

146 The arginine methyltransferase CARM1 (coactivator-associated arginine methyltransferase

147 g the H3-specific arginine methyltransferase CARM1 in individual blastomeres and show that this direc

148 ivator-associated arginine methyltransferase CARM1 is a positive regulator of ER alpha-mediated trans

149 ivator-associated arginine methyltransferase CARM1 is recruited by many different transcription facto

150 we show that the arginine methyltransferase CARM1 methylates BAF155, which differentially influences

151 arginine-specific histone methyltransferase CARM1.

152 0 coactivator, the protein methyltransferase CARM1, and any of the three protein acetyltransferases,

153 00 and CBP and the protein methyltransferase CARM1.

154 vator-associated arginine methyltransferase (CARM1) depends on the methyltransferase activity of CARM

155 vator-associated arginine methyltransferase (CARM1) is a transcriptional coactivator that methylates

156 vator-associated arginine methyltransferase (CARM1/PRMT4), during IFN-gamma-induced MHC-II gene activ

157 vator-associated arginine methyltransferase (CARM1/PRMT4)-mediated transcriptional coactivation and a

158 vator-associated arginine methyltransferase, CARM1, is a positive regulator of transcription.

159 inhibitor of the arginine methyltransferases CARM1 and PRMT6 was able to increase, in a gene specific

160 Surprisingly, mouse CARM1 expressed in insect and mammalian expression syste

161 he phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl don

162 tive to H3R2 methylation and that PRMT6, not CARM1/PRMT4, is the primary methyltransferase acting on

163 Notably, CARM1 stability is regulated by the SKP2-containing SCF

164 To unbiasedly investigate novel CARM1 PTMs we employed high-resolution top-down mass spe

165 Absence of CARM1 methyltransferase activity led to failure of cells

166 We previously reported that the absence of CARM1 partially blocks thymocyte differentiation at embr

167 In the absence of CARM1, alveolar type II cells show increased proliferati

168 understanding of the mechanism of action of CARM1 in oncogenesis has been limited by a lack of selec

169 These actions of CARM1 work together synergistically to regulate the expo

170 pendent on the methyltransferase activity of CARM1 and the acetyltransferase activity of p/CAF, but n

171 eport that the methyltransferase activity of CARM1 is negatively regulated through phosphorylation at

172 its specific chromatin modifying activity of CARM1 necessary for full potentiation of the BSEP locus

173 by inhibiting methyltransferase activity of CARM1, the enzyme responsible for H3R26 methylation, HIV

174 /p300, and the methyltransferase activity of CARM1.

175 depends on the methyltransferase activity of CARM1.

176 I required the methyltransferase activity of CARM1.

177 TLV-1 LTR promoter showed the association of CARM1 and methylated histone H3 with the template DNA.

178 BP is sufficient to drive the association of CARM1 with chromatin and methylation of R17 in vivo, whe

179 Our previous finding that automethylation of CARM1 is essential for regulation of transcription and p

180 sults strongly imply that automethylation of CARM1 provides a direct link to couple transcription and

181 er, our findings provide a signaling axis of CARM1-Pontin-FOXO3a and further expand the role of CARM1

182 In vitro, Tax facilitates the binding of CARM1 to the transcription complex.

183 Our findings suggest that coexpression of CARM1 and ERalpha may provide a better biomarker of well

184 Moreover, using the combination of CARM1 and PRMT6 inhibitors suppresses the cell prolifera

185 We propose that development of CARM1-specific inhibitors should focus on its N-terminus

186 We demonstrate that dimethylation of CARM1 occurs both in vivo and in vitro and proceeds via

187 w that embryos with a targeted disruption of CARM1 are small in size and die perinatally.

188 We demonstrate that disruption of CARM1 enhances the nuclear retention of mRNAs containing

189 Here we show that other domains of CARM1 are required for the coactivator function of CARM1

190 Here, we examined the effects of CARM1 inhibition on dendritic spine and synapse morpholo

191 on was severely attenuated by elimination of CARM1 or its methyltransferase activity, or by mutation

192 emonstrated that the coactivator function of CARM1 depends both on the methyltransferase activity and

193 are required for the coactivator function of CARM1 in addition to the methyltransferase activity.

194 To elucidate the functions of CARM1 in tumorigenesis, we knocked out CARM1 from severa

195 rue in zebrafish, in which, with the help of CARM1 inhibitor and CARM1 morpholinos, we show that inhi

196 ARM1 KO cell lines enabled identification of CARM1 substrates, notably the SWI/SNF core subunit BAF15

197 To unequivocally establish the importance of CARM1 enzymatic activity in vivo, we generated an enzyme

198 Similarly, pharmacological inhibition of CARM1 activity with the CARM1-specific inhibitor AMI-1 s

199 er, such mutation leads to the inhibition of CARM1 transactivation of estrogen receptor-dependent tra

200 EZM2302 (GSK3359088) is an inhibitor of CARM1 enzymatic activity in biochemical assays (IC50 = 6

201 the first potent and selective inhibitor of CARM1 that exhibits anti-proliferative effects both in v

202 Using a specific small-molecule inhibitor of CARM1-mediated H3R17 methylation in human embryonic stem

203 Thus, small molecule inhibitors of CARM1 will incapacitate all of the enzyme's cellular fun

204 d prostate adenocarcinomas, and knockdown of CARM1 inhibits proliferation of breast and prostate canc

205 This repression leads to increased levels of CARM1 protein and subsequent increases in histone H3 Arg

206 tron microscopy revealing co-localization of CARM1 with post-synaptic density (PSD)-95 protein, a pos

207 e observations, we hypothesized that loss of CARM1 in mouse embryos would inhibit pulmonary cell prol

208 By contrast, we report here that loss of CARM1 results in hyperproliferation of pulmonary epithel

209 Although mutation of CARM1's automethylation site did not affect its enzymati

210 Overexpression of CARM1 is implicated in a number of cancers, and it is th

211 studies demonstrated that overexpression of CARM1 wild-type protein resulted in increased Tax transa

212 activity at present, the C-terminal part of CARM1 contains an autonomous activation domain, suggesti

213 our results suggest that phosphorylation of CARM1 serves as a unique mechanism for inactivating CARM

214 dditionally, we find that the recruitment of CARM1 and subsequent histone arginine dimethylation are

215 ermore, phospho-SRC1-mediated recruitment of CARM1 induced prominent asymmetric dimethylation of H3R1

216 The sequential recruitment of CARM1 not only adds a protein arginine methyltransferase

217 The recruitment of CARM1 to the promoter requires endogenous CIITA and resu

218 ain, the unique N- and C-terminal regions of CARM1 were also required for enhancement of transcriptio

219 mation and that spatiotemporal regulation of CARM1 activity modulates neuronal connectivity and impro

220 However, the regulation of CARM1 enzymatic activity and substrate specificity remai

221 uronal progenitor specification, the role of CARM1 in any neuronal developmental pathways has been un

222 ter birth, demonstrating the crucial role of CARM1 in development.

223 e genetic evidence for the essential role of CARM1 in estrogen-mediated transcriptional activation.

224 Pontin-FOXO3a and further expand the role of CARM1 in nuclear regulation of autophagy.

225 tion is regulated by alternative splicing of CARM1 mRNA to remove exon 15, containing the automethyla

226 High-resolution crystal structures of CARM1 in complex with these compounds confirm a mode of

227 Specific siRNA-mediated suppression of CARM1 expression resulted in precocious dendritic matura

228 Gene targeting of CARM1 in mice has been performed, and knock-out mice, wh

229 nally, we demonstrate that the N-terminus of CARM1 is involved in substrate recognition and nearly in

230 subunits or CARM1 affected transcription of CARM1-regulated, estrogen-responsive genes.

231 Furthermore, either CARM1 knockdown or CARM1 enzyme-deficient mutant knockin resulted in decrea

232 Here, we showed that PRMT5, but not PRMT1 or CARM1, is essential for cell proliferation and PRMT5 def

233 Knockdown of either PAF1c subunits or CARM1 affected transcription of CARM1-regulated, estroge

234 ns of CARM1 in tumorigenesis, we knocked out CARM1 from several breast cancer cell lines using Zinc-F

235 lar level and 6- to 25-fold selectivity over CARM1, PRMT5, and PRMT8.

236 lation increased in cells that overexpressed CARM1.

237 and its downstream coactivators (e.g., p300, CARM1, CoCoA, and Fli-I), which contribute to transcript

238 omoter activation, including CBP/p300, PCAF, CARM1 and GRIP1.

239 These constructs were found to be potent CARM1 inhibitors and also formed stable complexes with t

240 rigenesis, we generated Cre-activated PRMT1, CARM1, and PRMT6 overexpression mouse models.

241 n motifs for three of these enzymes - PRMT1, CARM1 and PRMT9.

242 ifferent arginine methyltransferases, PRMT1, CARM1, and PRMT6, which are overexpressed in human cance

243 enerated multiple cell lines in which PRMT1, CARM1 and PRMT5 are inducibly knocked down.

244 require further investigation such as PRMT1/CARM1-induced transformation, CARM1-mediated delay in tu

245 at protein arginine methyltransferase PRMT4 (CARM1) methylates TP2 at Arg(71), Arg(75), and Arg(92) r

246 ss spectrometry approach to globally profile CARM1 substrates in breast cancer cell lines.

247 at phosphorylation at Ser(217) also promoted CARM1 cytoplasmic localization and that this translocati

248 one H3K18 residues, which, in turn, promotes CARM1 methylation activity on H3R17 residues to enhance

249 Comparative analysis of the published CARM1 crystal structures reveals that the hydroxyl group

250 Reciprocally, CARM1 stimulates the ATPase activity of BRG1, a key comp

251 Specific RNA interference reduced CARM1 expression as well as MHC-II expression.

252 XR regulatory element ligand, CDCA, requires CARM1 activity.

253 or further understanding the biological role CARM1 plays in cancer and other diseases.

254 Significantly, EZH2 inhibitor sensitizes CARM1-high, but not CARM-low, EOCs to PARP inhibitors in

255 identify a new signalling axis of AMPK-SKP2-CARM1 in the regulation of autophagy induction after nut

256 Surprisingly, CARM1-Pontin-FOXO3a signaling axis can work in the dista

257 CARM1 and PRMT6 are noticeably smaller than CARM1 null embryos, providing in vivo evidence of redund

258 methylate different protein substrates than CARM1, could not substitute for CARM1 to act synergistic

259 These results demonstrate that CARM1 plays a significant role in promoting the differen

260 Our findings demonstrate that CARM1-dependent histone arginine methylation is a crucia

261 aken together, this report demonstrates that CARM1 is a key epigenetic regulator of hematopoiesis tha

262 Together, our data provide evidence that CARM1 enhances Tax transactivation of the HTLV-1 LTR thr

263 We propose that CARM1 is a dual-function coactivator, as it not only act

264 It has been proposed that CARM1 has functions that are independent of its enzymati

265 Here, we report that CARM1 also methylates Arg-2142 within the C-terminal GRI

266 In this study, we report that CARM1 function is regulated by phosphorylation at Ser(21

267 Cancer Cell, Wang and colleagues report that CARM1, a protein arginine methyltransferase, specificall

268 Genome-wide analyses reveal that CARM1 exerts transcriptional co-activator function on au

269 r and the endogenous CD44 gene revealed that CARM1 promotes exon skipping in an enzyme-dependent mann

270 Here, we show that CARM1 is essential for estrogen-induced cell cycle progr

271 cells in a CARM1-sufficient host showed that CARM1 is required cell autonomously in hematopoietic cel

272 ) FL cells on OP9-DL1 monolayers showed that CARM1 is required for survival of hematopoietic progenit

273 Here it is shown that CARM1 binds to beta-catenin and can function in synergy

274 Previous work has shown that CARM1 can methylate CBP at three arginine residues.

275 These results suggest that CARM1 is a post-synaptic protein that plays roles in den

276 results demonstrate for the first time that CARM1 inhibits pulmonary cell proliferation and is requi

277 The CARM1 KO cell lines enabled identification of CARM1 subs

278 nction in neurons, little is known about the CARM1 cellular location and its role in dendritic matura

279 ed reflective of the transition state at the CARM1 active site.

280 ild-type CBP and a mutant of CBP lacking the CARM1-targeted arginine residues (R3A), we show that arg

281 The crystal structures of the CARM1 catalytic core in the apo and holo states reveal c

282 ompounds such as JQ1 or vorinostat/SAHA, the CARM1 inhibitor achieved synergistic effects on HIV-1 ac

283 ogical inhibition of CARM1 activity with the CARM1-specific inhibitor AMI-1 significantly increased s

284 Thus, CARM1 is a critical factor in the pathway of estrogen-st

285 on additional unknown proteins that bind to CARM1.

286 Fli-I bound to CARM1, GRIP1, and NRs and cooperated synergistically wit

287 stimulation, the E2F1 promoter is subject to CARM1-dependent dimethylation on histone H3 arginine 17

288 AB1) and pleiotropic genes for lipid traits (CARM1).

289 such as PRMT1/CARM1-induced transformation, CARM1-mediated delay in tumorigenesis, and PRMTs potenti

290 In human breast tumors, CARM1 expression positively correlated with ERalpha leve

291 can also deposit the H3R17me2a mark in vitro CARM1 knockout mice are perinatally lethal and display a

292 EZM2302 demonstrates dose-dependent in vivo CARM1 inhibition and anti-tumor activity in an MM xenogr

293 In vivo, CARM1 and BRG1 coassemble on an estrogen receptor (ER)-t

294 th an intact FXR regulatory element, whereas CARM1 failed to transactivate the BSEP promoter with a m

295 The current study tested whether CARM1 can cooperate with other types of coactivator prot

296 scription activation, the mechanism by which CARM1 activates transcription remains unclear.

297 To understand the mechanism by which CARM1 functions, we sought to isolate its substrates.

298 was recruited to the ER promoter along with CARM1, CBP, c-Jun, and Sp1 and that this multifactor com

299 the H3R17me2a mark and acts redundantly with CARM1.

300 and NRs and cooperated synergistically with CARM1 and GRIP1 to enhance NR function.